Literature DB >> 22933546

Frequent expression of fibroblast growth factor-23 (FGF23) mRNA in aneurysmal bone cysts and chondromyxoid fibromas.

Rondell Graham1, Smita Krishnamurthy, Andre Oliveira, Carrie Inwards, Andrew L Folpe.   

Abstract

Osteomalacia has multiple aetiologies including the least common, tumour-induced osteomalacia (TIO). Recently, most cases of TIO have been confirmed to be due to phosphaturic mesenchymal tumour of mixed connective tissue type (PMTMCT). Most cases of TIO are the result of production of the fibroblast growth factor-23 (FGF-23) by the tumour. The authors recently showed reverse transcriptase PCR (RT-PCR) for FGF-23 to be valuable in the diagnosis of PMTMCT. However, the authors also noted FGF-23 expression in some cases of aneurysmal bone cyst (ABC) and chondromyxoid fibroma (CMF). For the present study, the authors studied FGF-23 expression by RT-PCR in 19 cases of ABC and eight cases of CMF, all with typical clinical and radiographic features and without evidence of TIO. Seven of 16 (44%) ABC and two of seven (29%) CMF were positive for FGF-23. These results confirm that ABC and CMF not uncommonly express FGF-23. These results strongly suggest caution and careful integration with all other clinical and radiographic data in the use of FGF-23 RT-PCR for the diagnosis of PMTMCT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22933546     DOI: 10.1136/jclinpath-2012-200852

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  6 in total

Review 1.  [Tumor-induced osteomalacia caused by an FGF23-secreting myopericytoma : Case report and literature review].

Authors:  N Muro Bushart; L Tharun; R Oheim; A Paech; J Kiene
Journal:  Orthopade       Date:  2020-01       Impact factor: 1.087

2.  Phosphaturic mesenchymal tumor: two contrasting cases.

Authors:  Monica C Koplas; Brian P Rubin; Murali Sundaram
Journal:  Skeletal Radiol       Date:  2014-01-09       Impact factor: 2.199

3.  CD56 may be a more useful immunohistochemical marker than somatostatin receptor 2A for the diagnosis of phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

4.  Phosphaturic mesenchymal tumour mixed connective tissue variant: report of three cases with unusual histological findings.

Authors:  David A Shustik; David Ce Ng; Kesavan Sittampalam
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

5.  Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the femur: A case report.

Authors:  Dong Tang; Xiao-Man Wang; Yong-Sheng Zhang; Xiao-Xiao Mi
Journal:  World J Clin Cases       Date:  2019-08-06       Impact factor: 1.337

6.  Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant.

Authors:  Eisuke Shiba; Atsuji Matsuyama; Ryo Shibuya; Kei Yabuki; Hiroshi Harada; Mitsuhiro Nakamoto; Takahiko Kasai; Masanori Hisaoka
Journal:  Diagn Pathol       Date:  2016-03-09       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.